Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by funky99on Sep 01, 2016 10:01am
122 Views
Post# 25198798

RE:RE:As a Long, What Discourages Me?

RE:RE:As a Long, What Discourages Me?I personnally think the Biotech sector in Canada has suffered for a while compared to the US. Money has flowned in the traditionnal healthcare pharma sector the last couple of years. I believe in innovation in drugs and there is value there. Eventually, market will recognize it. Check Cynapsus Therapeutics Inc CTH.V who was acuired by Sunovion Pharmaceuticals. Shares were trading at around 0.35$ in 2013. Look at the history there has been multiple financing and dillution as well. Unfortunately, nothing happens in a day for a company in development. I like the prospect of ATB-346 drugs, think it is a need in the market, the Board of Directors and management is solid imo. If you don't like, sell and move on. On my end, I will wait patiently.
Bullboard Posts